NCT04278898View on ClinicalTrials.gov

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

January 31, 2027

Conditions
Autism Spectrum Disorder
Interventions
DRUG

N-Acetylcysteine

N-acetylcysteine Single Dose 2700 mg taken orally

Trial Locations (1)

94305

RECRUITING

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Stanford University

OTHER